Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure.
Biomarkers
Clinical needs
Registry
Renal cancer
Renal cell carcinoma
Journal
Clinical genitourinary cancer
ISSN: 1938-0682
Titre abrégé: Clin Genitourin Cancer
Pays: United States
ID NLM: 101260955
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
31
08
2020
revised:
15
10
2020
accepted:
16
10
2020
pubmed:
29
12
2020
medline:
10
8
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
Close to 74,000 cases of renal cell carcinoma (RCC) are diagnosed each year in the United States. The past 2 decades have shown great developments in surgical techniques, targeted therapy and immunotherapy agents, and longer complete response rates. However, without a global cure, there is still room for further advancement in improving patient care in this space. To address some of the gaps restricting this progress, the Kidney Cancer Association brought together a group of 27 specialists across the areas of clinical care, research, industry, and advocacy at the inaugural "Think Tank: Coalition for a Cure" session. Topics addressed included screening, imaging, rarer RCC subtypes, combination drug therapy options, and patient response. This commentary summarizes the discussion of these topics and their respective clinical challenges, along with a proposal of projects for collaboration in overcoming those needs and making a greater impact on care for patients with RCC moving forward.
Identifiants
pubmed: 33358149
pii: S1558-7673(20)30234-2
doi: 10.1016/j.clgc.2020.10.005
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
167-175Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.